VAXCYTE, INC. Proceeds from Stock Options Exercised
VAXCYTE, INC. (PCVX) reported Proceeds from Stock Options Exercised of $6.05 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2025-05-07
- VAXCYTE, INC. proceeds from stock options exercised for the quarter ending 2025-03-31 was $6.05M, a 20.40% increase year-over-year.
- VAXCYTE, INC. proceeds from stock options exercised for the quarter ending 2024-09-30 was $11.74M, a 444.64% increase year-over-year.
- VAXCYTE, INC. proceeds from stock options exercised for the quarter ending 2024-06-30 was $2.74M, a 210.41% increase year-over-year.
- VAXCYTE, INC. proceeds from stock options exercised for the quarter ending 2024-03-31 was $5.02M, a 900.80% increase year-over-year.
- VAXCYTE, INC. proceeds from stock options exercised for fiscal 2023 was $5.61M, a 14.57% increase from fiscal 2022.
- VAXCYTE, INC. proceeds from stock options exercised for fiscal 2022 was $4.89M, a 62.52% increase from fiscal 2021.
- VAXCYTE, INC. proceeds from stock options exercised for fiscal 2021 was $3.01M, a 374.33% increase from fiscal 2020.
- VAXCYTE, INC. proceeds from stock options exercised for fiscal 2020 was $635.00K, a 97.20% increase from fiscal 2019.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2025-03-31 | $6.05M 10-Q · filed 2025-05-07 | |||
| 2024-09-30 | $11.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $14.48M derived: sum of 2 quarters · filed 2024-11-05 | $19.50M 10-Q · filed 2024-11-05 | $21.57M derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-06-30 | $2.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $7.77M 10-Q · filed 2024-08-06 | $9.84M derived: sum of 3 quarters · filed 2025-05-07 | $11.99M derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-03-31 | $5.02M 10-Q · filed 2025-05-07 | $7.09M derived: sum of 2 quarters · filed 2025-05-07 | $9.25M derived: sum of 3 quarters · filed 2025-05-07 | $10.13M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $4.22M derived: sum of 2 quarters · filed 2024-11-05 | $5.11M derived: sum of 3 quarters · filed 2024-11-05 | $5.61M 10-K · filed 2024-02-27 |
| 2023-09-30 | $2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $3.04M derived: sum of 2 quarters · filed 2024-11-05 | $3.54M 10-Q · filed 2024-11-05 | $6.07M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $884.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.39M 10-Q · filed 2024-08-06 | $3.92M derived: sum of 3 quarters · filed 2024-08-06 | $5.67M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $502.00K 10-Q · filed 2024-05-08 | $3.03M derived: sum of 2 quarters · filed 2024-05-08 | $4.79M derived: sum of 3 quarters · filed 2024-05-08 | $5.12M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $4.29M derived: sum of 2 quarters · filed 2024-02-27 | $4.61M derived: sum of 3 quarters · filed 2024-02-27 | $4.89M 10-K · filed 2024-02-27 |
| 2022-09-30 | $1.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $2.08M derived: sum of 2 quarters · filed 2023-11-06 | $2.36M 10-Q · filed 2023-11-06 | $3.93M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $324.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $606.00K 10-Q · filed 2023-08-08 | $2.17M derived: sum of 3 quarters · filed 2024-02-27 | $2.67M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $282.00K 10-Q · filed 2023-05-08 | $1.85M derived: sum of 2 quarters · filed 2024-02-27 | $2.34M derived: sum of 3 quarters · filed 2024-02-27 | $2.81M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $2.06M derived: sum of 2 quarters · filed 2024-02-27 | $2.52M derived: sum of 3 quarters · filed 2024-02-27 | $3.01M 10-K · filed 2024-02-27 |
| 2021-09-30 | $491.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $957.00K derived: sum of 2 quarters · filed 2022-11-07 | $1.44M 10-Q · filed 2022-11-07 | $1.63M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $466.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $953.00K 10-Q · filed 2022-08-08 | $1.13M derived: sum of 3 quarters · filed 2023-02-27 | $1.24M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $487.00K 10-Q · filed 2022-05-09 | $668.00K derived: sum of 2 quarters · filed 2023-02-27 | $776.00K derived: sum of 3 quarters · filed 2023-02-27 | $1.07M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $181.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $289.00K derived: sum of 2 quarters · filed 2023-02-27 | $586.00K derived: sum of 3 quarters · filed 2023-02-27 | $635.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $108.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $405.00K derived: sum of 2 quarters · filed 2021-11-10 | $454.00K 10-Q · filed 2021-11-10 | $461.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $297.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $346.00K 10-Q · filed 2021-08-11 | $353.00K derived: sum of 3 quarters · filed 2022-02-28 | $666.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $49.00K 10-Q · filed 2021-05-11 | $56.00K derived: sum of 2 quarters · filed 2022-02-28 | $369.00K derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $320.00K derived: sum of 2 quarters · filed 2022-02-28 | $322.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $313.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $315.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $2.00K 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $5.00K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |